Characterisation and strategic treatment of dystrophic muscle

PhD Thesis


Laws, Nicola. 2005. Characterisation and strategic treatment of dystrophic muscle. PhD Thesis Doctor of Philosophy. University of Southern Queensland.
Title

Characterisation and strategic treatment of dystrophic muscle

TypePhD Thesis
Authors
AuthorLaws, Nicola
SupervisorHoey, Andrew
Institution of OriginUniversity of Southern Queensland
Qualification NameDoctor of Philosophy
Number of Pages246
Year2005
Abstract

The mdx mouse is widely used as a model for Duchenne Muscular Dystrophy, a fatal X-linked disease caused by a deficiency of the sub-sarcolemmal protein, dystrophin. This dissertation reports characterisation of the features of dystrophy in the mdx mouse, including parameters such as electrophysiological and contractile properties of dystrophic cardiac tissue, quantitative evaluation of kyphosis throughout the mdx lifespan, and contractile properties of respiratory and paraspinal muscles. Following these characterisation studies, the efficacy of antisense oligonucleotides (AOs) to induce alternative mRNA splicing in mdx skeletal muscles (diaphragm and paraspinal muscles) was evaluated. The left atria of younger (<6 weeks) and older (>15 months) mdx mice showed consistently lower basal forces and responsiveness to increased calcium, while action potential duration was significantly shorter in young mice (3 weeks) and older mice (9 and 12 months) (P<0.05). Cardiac fibrosis increased with age in mdx atria and ventricles and was elevated in young (6-8 weeks) and old (15 months) mdx compared to control mice (P<0.01). This study provided insights into DMD cardiomyopathy, and suggested that very young or old mdx mice provide the most useful models. Mdx mice show thoracolumbar kyphosis like boys with Duchenne Muscular Dystrophy. A novel radiographic index, the Kyphotic Index (KI), was developed and showed that mdx mice are significantly more kyphotic from 9 months of age, an effect maintained until 17 months (P<0.05). At 17 months, the paraspinal and respiratory muscles (latissimus dorsi, diaphragm and intercostal muscles) are significantly weaker and more fibrotic (P<0.05). Administration of AOs at four sites within the diaphragm at 4 and 5 months of age significantly increased twitch and tetanic forces compared to sham treated mdx (P<0.05). However, no difference in collagen was evident and dystrophin was not detected, possibly due to the low concentration of AO utilised. This study suggested that AOs can provide functional improvement in treated skeletal muscles. Monthly injections with AOs into the paraspinal muscles from 2 months to 18 months of age alleviated kyphosis, without significantly altering twitch and tetanic forces of latissimus dorsi, diaphragm and intercostal muscles. There was evidence of less fibrosis in diaphragm and latissimus dorsi muscles (P<0.05) and reduced central nucleation of the latissimus dorsi and intercostal muscles (P<0.05). Again, dystrophin was not detected by immunoblot. These studies indicate that very young and old mdx mice display previously uncharacterised dystrophic features, and are useful models for testing new therapies such as AOs. Low doses of AOs were shown to be safe and efficacious for long-term use, however there remains a need for testing higher concentrations and improved delivery strategies.

Keywordsdystrophic muscle, Duchenne Muscular Dystrophy (DMD), antisense oligonucleotides (AOs), dystrophin, muscular dystrophy X-linked mouse (mdx)
ANZSRC Field of Research 2020310912. Comparative physiology
310910. Animal physiology - systems
320506. Medical biochemistry - proteins and peptides (incl. medical proteomics)
Permalink -

https://research.usq.edu.au/item/9xxy7/characterisation-and-strategic-treatment-of-dystrophic-muscle

Download files


Published Version
Laws_2005_whole.pdf
File access level: Anyone

  • 2287
    total views
  • 999
    total downloads
  • 0
    views this month
  • 0
    downloads this month

Export as